{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:26:56Z","timestamp":1777890416649,"version":"3.51.4"},"reference-count":10,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Renal cell carcinoma (RCC) is the most common kidney cancer in adults. The advent of immune checkpoint inhibitors (ICIs), particularly in combination with tyrosine kinase inhibitors (TKIs), has significantly improved outcomes in advanced disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 67-year-old woman with stage IV clear cell RCC and intermediate-risk features presented with pulmonary, nodal, and peritoneal metastases. She received first-line pembrolizumab plus axitinib, achieving durable disease control and partial response with good tolerability. After 32 months she achieved sustained disease stability and underwent robot-assisted left nephrectomy. Histology revealed complete pathological response. Postoperatively, pembrolizumab was continued with a pseudo-adjuvant intent, and as of March 2026, the patient remains in radiological near-complete response with a progression-free survival of approximately 41 months from treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusions<\/jats:title>\n                    <jats:p>This case illustrates that ICI\u2013TKI combinations can induce profound and durable responses even in intermediate-risk metastatic RCC. Consolidative surgery after systemic control, though still under debate, may be beneficial for carefully selected patients. Overall, this report underscores the potential of immunotherapy\u2013TKI combinations to achieve long-term remission and the importance of a multidisciplinary, personalized treatment approach in advanced RCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1811163","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:18Z","timestamp":1777613838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete response in metastatic clear cell renal cell carcinoma following pembrolizumab\u2013axitinib and subsequent nephrectomy: a Case Report"],"prefix":"10.3389","volume":"17","author":[{"given":"Mariam Grazia","family":"Polito","sequence":"first","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Caruso","sequence":"additional","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Cosimati","sequence":"additional","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Adriana","family":"Ramirez Reinaga","sequence":"additional","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etien","family":"Leka","sequence":"additional","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fuschi","sequence":"additional","affiliation":[{"name":"Department of Urology Universit\u00e0 \u201cLa Sapienza\u201d, ICOT Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Luigi","family":"Pastore","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science and Biotechnology, Universit\u00e0 \u201cLa Sapienza\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Carbone","sequence":"additional","affiliation":[{"name":"Department of Urology Universit\u00e0 \u201cLa Sapienza\u201d, ICOT Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostika","family":"Lako","sequence":"additional","affiliation":[{"name":"Department of Medico-Surgical Sciences and Biotechnologies Histopathology, Sapienza University of Rome Faculty of Pharmacy and Medicine","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Di Cristofano","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science and Biotechnology, Universit\u00e0 \u201cLa Sapienza\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Petrozza","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science and Biotechnology, Universit\u00e0 \u201cLa Sapienza\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Science and Biotechnology, Universit\u00e0 \u201cLa Sapienza\u201d","place":["Rome, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Paolo","family":"Spinelli","sequence":"additional","affiliation":[{"name":"UOC Oncologia Territoriale \u2013 ASL Latina \u2013 CDS Aprilia, La Sapienza Universit\u00e0 Di Roma Polo Pontino","place":["Latina, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1615795","article-title":"Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy","volume":"15","author":"Nayak","year":"2025","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomized, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102994","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomized CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.urolonc.2024.01.044","article-title":"SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597","volume":"42","author":"Jeyakumar","year":"2024","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313906","article-title":"Belzutifan versus everolimus for advanced renal-cell carcinoma","volume":"391","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40425-017-0287-5","article-title":"Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy","volume":"5","author":"Vaishampayan","year":"2017","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:37:18Z","timestamp":1777613838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1811163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":10,"alternative-id":["10.3389\/fimmu.2026.1811163"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1811163","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"article-number":"1811163"}}